Nipent (Pentostatin)

Pentostatin inhibits the enzyme adenosine deaminase, which leads to a buildup of deoxyadenosine nucleotides inside lymphocytes. This accumulation interferes with DNA synthesis and repair, causing programmed cell death of the malignant B‑cells that drive the leukemia or lymphoma.

The dose of Nipent is individualized by the prescribing physician based on factors such as the patient’s weight, renal and hepatic function, disease severity, and response to prior therapy. No fixed dosing regimen is provided here; the prescriber sets the appropriate schedule.

The safety of pentostatin in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug may pose risks to the fetus or infant. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally not recommended during treatment.

To order Nipent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Pentostatin belongs to the purine analog class, offering a distinct mechanism compared with alkylating agents or monoclonal antibodies. In hairy cell leukemia, it provides high response rates and can be used when patients are refractory to cladribine. For chronic lymphocytic leukemia, it is often combined with other chemotherapeutics, offering an alternative for patients who cannot tolerate more intensive regimens.

Nipent should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period, it may be used promptly, but it should be returned to refrigeration as soon as possible.

Nipent is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician, typically over several minutes to an hour, depending on the treatment protocol and patient tolerance.

The most serious risks include severe myelosuppression leading to neutropenia and life‑threatening infections, hepatic toxicity, renal impairment, and rare but severe allergic reactions such as anaphylaxis. Continuous monitoring of blood counts, liver and kidney function is essential to detect these complications early.

Patients with active uncontrolled infections, severe hepatic or renal dysfunction, known hypersensitivity to pentostatin or any component of the formulation, and those who are pregnant or breastfeeding without appropriate risk‑benefit assessment should not receive Nipent. The prescriber must evaluate each individual’s medical history before initiating therapy.